ATP2C1

Across TCGA pan-cancer cohorts, ATP2C1 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated ATP2C1 data layer compared with 8 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ATP2C1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ATP2C1 expression acts as an unfavorable survival marker, although some lineages such as KIRC and HNSC show a favorable association.

MESO, KIRC, and PAAD are the cancer types where ATP2C1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.235	0.515	.001	114	view →
KIRC	DFS	Tertile	All	0.741	0.520	<.001	73	view →
PAAD	OS	Tertile	All	0.336	0.661	<.001	60	view →
LIHC	DFS	Median	All	0.447	0.636	<.001	57	view →
HNSC	DFS	Median	All	0.442	0.275	<.001	43	view →
LUSC	OS	Median	II,III,IV	0.801	0.653	.002	23	view →
UVM	OS	Quartile	All	0.955	0.616	.005	22	view →
ACC	DFS	Quartile	II,III,IV	0.498	0.883	<.001	20	view →
SARC	DFS	Tertile	All	0.271	0.565	.001	20	view →
PRAD	DFS	Median	All	0.869	0.697	.001	16	view →
UCS	DFS	Tertile	IV	0.978	0.364	.024	12	view →
CHOL	DFS	Median	All	0.626	0.187	.007	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

ATP2C1–MESO (OS)

Open the MESO breakdown →